Navigation Links
Biosimilars Market Expected to Soar
Date:2/14/2013

LONDON, Feb. 14, 2013 /PRNewswire/ -- Top representatives from the healthcare industry are confirmed to attend the 2nd Biosimilars Congregation which will take place in London on the 19th and 20th of February 2013. Ranjith Gopinathan , Frost & Sullivan Program Manager for Life Sciences, Europe Practice, is set to participate to the event's Keynote Panel Discussion focusing on challenges and opportunities in the global biosimilars market.

"Experience in biosimilars development, manufacturing and commercialisation in regulated markets such as Europe and the US is limited. Furthermore, reluctance from some physicians and patients to adopt biosimilars due to perceived efficacy and safety issues could have an adverse impact on market penetration. Such uncertainties, in addition to the complex regulatory pathway, compound the risks for biosimilars manufacturers," says Ranjith Gopinathan , Frost & Sullivan Program Manager for Life Sciences, Frost & Sullivan.

Initially, manufacturers of biosimilars will focus on the 3 protein classes of erythropoiein and human growth hormone due to their recent patent expiry. In the long run, insulin, interferon and more complex proteins like monoclonal antibodies are likely to emerge.  However, some companies may concentrate on certain therapeutic classes depending on their capabilities and strategic fit.

Europe has the highest number of biosimilars approvals in the regulated market and will continue to increase in the near future. Further patent expiries of biologics will likely increase the number of approved biosimilars and players in the market and thereby will bring in a greater number of products that will increase the market size. Biosimilars are currently priced at about 20-30% below the original product price.

The 2nd Biosimilars Congregation 2013, which is organised by Virtue Insight, will bring together top pharmaceutical, biotechnology and regulatory representatives under one roof, who will address the industry key issues - ranging from the evolving regulatory landscape and challenges in clinical development, to the legal and economic aspects. The event will take place in London, UK, on the 19th and 20th of February.

For more information please click on the following link or contact fen.castro@virtueinsight.com - http://www.virtueinsight.com/pharma/2nd-Biosimilars-Congregation-2013/

About Virtue Insight
Virtue Insight equips business professionals around the world with the latest in-depth industry knowledge and provides networking opportunities in the telecom, infrastructure and pharmaceutical industry. Our aim is to provide a platform to share knowledge and insights and provide our event attendees to network effectively and deliver maximum ROI by make new business alliances. We strive to produce high quality conferences which include the latest topics which are delivered by world class leaders of the industry. 

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies? Contact us: Start the discussion

Contact

Fen Castro
Head - Productions
Virtue Insight
P (India) + 0091 44 64998743; Mob + 91 9003 26 0693
P (UK) + 44 2033024659; Mob + 44 7424406352
E: fen.castro@virtueinsight.com
www.virtueinsight.com

Anna Zanchi
Corporate Communications – Europe
Frost & Sullivan
P: +39.02.4851 6133
E: anna.zanchi@frost.com
http://www.frost.com


'/>"/>
SOURCE Frost & Sullivan
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. FDA New Guidelines for Biosimilars and Biobetters: An Outlook for 2013
2. UBM Conferences Unveils Details for Upcoming Generics and Biosimilars Conference
3. Biosimilars: Global Markets
4. Despite Recession, Global Biosimilars Market Grew Over 40% 2010-2011, Set to Reach $3.6 Billion by 2016
5. Immune Deficiency Foundation Urges FDA To Exempt Immunoglobulin From Biosimilars Pathway
6. Nektar to Announce Financial Results for the Fourth Quarter and Year-End of 2012 On Thursday, February 28, 2013, After Close of U.S.-Based Financial Markets
7. Intraocular Lens (IOL) Market Worth $3.8 Billion By 2018 Say New Research Report at ReportsnReports.com
8. New Product Launch: Are your Strategies for Emerging Healthcare and Life Sciences Markets Innovative and Structured?
9. Regenerative Medicine and Stem Cells Market Deals Analysis in New Research Report at ReportsnReports.com
10. Plunketts Biotech & Genetics Industry Almanac 2013: Biotech & Genetics Industry Market Research, Statistics, Trends & Leading Companies
11. Cellular Therapy Market and Cord Blood Market 2013 Industry Research Report: MarketResearchReports.Biz
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... NY (PRWEB) , ... January 20, 2017 , ... Nipro ... a Joint Venture (JV) under which Nipro will receive exclusive marketing and sales rights ... to establish best practices for hemodialysis patients in Japan, the new Nipro - Transonic ...
(Date:1/21/2017)... 2017 Interpace Diagnostics Group, Inc. (NASDAQ: ... clinically useful molecular diagnostic tests and pathology services, ... securities purchase agreement with three  institutional investors to ... stock in a registered direct offering.  In a ... sell to the same investors warrants to purchase ...
(Date:1/21/2017)... Kan. , Jan. 20, 2017 Aratana ... therapeutics company focused on the licensing, development and commercialization ... Animal Pharm,s Best Company in North ... granted the award based on the FDA ... (grapiprant tablets), ENTYCE ® (capromorelin oral solution) ...
(Date:1/20/2017)... ... 2017 , ... The two newest companies to join the University City Science ... out from The Wistar Institute, and Sanguis, launched by a trio of students from ... , Vironika is developing a treatment for a chronic viral infection and its associated ...
Breaking Biology Technology:
(Date:12/20/2016)... and GENEVA, Dec, 20, 2016   Valencell ... sensor technology, and STMicroelectronics (NYSE: STM), a ... of electronics applications, announced today the launch of ... for biometric wearables that includes ST,s compact ... Valencell,s Benchmark™ biometric sensor system. Together, SensorTile ...
(Date:12/16/2016)... --  IdentyTechSolutions America LLC , a leading provider ... a cutting-edge manufacturer of software and hardware security ... integrated solutions that comprise IDT biometric readers and ... IdentyTech,s customers with combined physical identification and anti-tailgating ... theft. "We are proud to use ...
(Date:12/16/2016)... , Dec. 16, 2016 The global wearable medical device ... billion by 2021 from USD 5.31 billion in 2016, at a ... ... driven by technological advancements in medical devices, launch of a growing ... for wireless connectivity among healthcare providers, and increasing focus on physical ...
Breaking Biology News(10 mins):